Dipeptide Comprising a Non-Proteogenic Amino Acid
US-2019002496-A1 · Jan 3, 2019 · US
3-desoxy derivative and pharmaceutical compositions thereof
US11319337B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11319337-B2 |
| Application number | US-202017025475-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 18, 2020 |
| Priority date | Mar 11, 2016 |
| Publication date | May 3, 2022 |
| Grant date | May 3, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present application provides Compound 1:or a pharmaceutically acceptable salt or amino acid conjugate thereof. The present invention relates to an FXR activator and to methods of making and using said compound.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating a chronic liver disease, comprising administering to a subject in need thereof an effective amount of compound (1) or a pharmaceutically acceptable salt or amino acid conjugate thereof. 2. The method of claim 1 , comprising administering compound (1). 3. The method of claim 1 , comprising administering a pharmaceutically acceptable salt of compound (1). 4. The method of claim 1 , comprising administering a pharmaceutically acceptable amino acid conjugate of compound (1). 5. The method of claim 4 , wherein the amino acid conjugate is glycine conjugate or sarcosine conjugate. 6. The method of claim 1 , wherein the chronic liver disease is primary biliary cirrhosis (PBC), cerebrotendinous xanthomatosis (CTX), primary sclerosing cholangitis (PSC), drug induced cholestasis, intrahepatic cholestasis of pregnancy, parenteral nutrition associated cholestasis (PNAC), bacterial overgrowth or sepsis associated cholestasis, autoimmune hepatitis, chronic viral hepatitis, alcoholic liver disease, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), liver transplant associated graft versus host disease, living donor transplant liver regeneration, congenital hepatic fibrosis, choledocholithiasis, granulomatous liver disease, intra- or extrahepatic malignancy, Sjogren's syndrome, Sarcoidosis, Wilson's disease, Gaucher's disease, hemochromatosis, or alphal-antitrypsin deficiency. 7. The method of claim 1 , wherein the chronic liver disease is nonalcoholic fatty liver disease (NAFLD). 8. The method of claim 1 , wherein the chronic liver disease is nonalcoholic steatohepatitis (NASH). 9. The method of claim 1 , wherein the chronic liver disease is primary biliary cirrhosis (PBC).
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
- C07J11/00Primary
Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3 · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title
Anorexiants; Antiobesity agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11319337B2 cover?
- The present application provides Compound 1:or a pharmaceutically acceptable salt or amino acid conjugate thereof. The present invention relates to an FXR activator and to methods of making and using said compound.
- Who is the assignee on this patent?
- Intercept Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification C07J11/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).